Enanta Pharmaceuticals (STU:9EP) E10: €-1.97 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9EP Enanta Pharmaceuticals Inc STU:9EP
58 GF Score
Price €11.50
GF Value €7.57
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Enanta Pharmaceuticals E10?

Enanta Pharmaceuticals STU:9EP 58 E10 is €-1.97 as of Mar. 2026. GuruFocus rates STU:9EP with a GF Score™ of 58/100 and a GF Value™ of €7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Enanta Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.389. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.97 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-16), Enanta Pharmaceuticals's current stock price is €11.50. Enanta Pharmaceuticals's E10 for the quarter that ended in Mar. 2026 was €-1.97. Enanta Pharmaceuticals's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Enanta Pharmaceuticals was 1348.00. The lowest was 110.03. And the median was 220.41.


Enanta Pharmaceuticals  (STU:9EP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Enanta Pharmaceuticals was 1348.00. The lowest was 110.03. And the median was 220.41.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Enanta Pharmaceuticals E10 Related Terms


Enanta Pharmaceuticals E10 Historical Data

* Premium members only.

The historical data trend for Enanta Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enanta Pharmaceuticals E10 Chart

Enanta Pharmaceuticals Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.27 0.24 -0.22 -0.89 -2.11

Enanta Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.56 -1.53 -2.11 -1.92 -1.97

STU:9EP vs PBYI, IPSC, BNTC: E10 Comparison

For the Biotechnology subindustry, Enanta Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enanta Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enanta Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Enanta Pharmaceuticals's Shiller PE Ratio falls into.


STU:9EP
58GF Score
Enanta Pharmaceuticals Inc STU:9EP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Enanta Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Enanta Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.389/330.2130*330.2130
=-0.389

Current CPI (Mar. 2026) = 330.2130.

Enanta Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201606 -0.053 241.018 -0.073
201609 -0.080 241.428 -0.109
201612 -0.246 241.432 -0.336
201703 -0.262 243.801 -0.355
201706 -0.392 244.955 -0.528
201709 1.561 246.819 2.088
201712 0.499 246.524 0.668
201803 0.495 249.554 0.655
201806 0.830 251.989 1.088
201809 1.114 252.439 1.457
201812 1.099 251.233 1.444
201903 0.177 254.202 0.230
201906 0.292 256.143 0.376
201909 0.400 256.759 0.514
201912 0.585 256.974 0.752
202003 -0.271 258.115 -0.347
202006 -0.630 257.797 -0.807
202009 -1.240 260.280 -1.573
202012 -0.337 260.474 -0.427
202103 -0.916 264.877 -1.142
202106 -0.988 271.696 -1.201
202109 -1.037 274.310 -1.248
202112 -1.310 278.802 -1.552
202203 -1.480 287.504 -1.700
202206 -1.447 296.311 -1.613
202209 -1.283 296.808 -1.427
202212 -1.312 296.797 -1.460
202303 -1.672 301.836 -1.829
202306 -1.717 305.109 -1.858
202309 -1.246 307.789 -1.337
202312 -1.449 306.746 -1.560
202403 -1.352 312.332 -1.429
202406 -0.994 314.175 -1.045
202409 -1.225 315.301 -1.283
202412 -1.003 315.605 -1.049
202503 -0.980 319.799 -1.012
202506 -0.737 322.561 -0.754
202509 -0.741 324.800 -0.753
202512 -0.359 324.054 -0.366
202603 -0.389 330.213 -0.389

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-1.97 mean?
Enanta Pharmaceuticals (STU:9EP) has a E10 of €-1.97 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors.
Is Enanta Pharmaceuticals' E10 too high?
Enanta Pharmaceuticals' current E10 is €-1.97. Overall, Enanta Pharmaceuticals has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Enanta Pharmaceuticals' E10 compare to PBYI and IPSC?
Enanta Pharmaceuticals' E10 of €-1.97 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Enanta Pharmaceuticals and its competitors. Enanta Pharmaceuticals's current E10 is €-1.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enanta Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Enanta Pharmaceuticals (STU:9EP) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.57, compared to a current price of €11.50 — trading 51.9% above its estimated fair value. The current E10 is €-1.97. Enanta Pharmaceuticals' overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Enanta Pharmaceuticals (STU:9EP), the current E10 is €-1.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Enanta Pharmaceuticals (STU:9EP) Overvalued in 2026?

Based on GuruFocus' analysis, Enanta Pharmaceuticals stock appears to be overvalued. The current stock price of €11.50 is trading 51.9% above its estimated GF Value™ of €7.57. GuruFocus considers Enanta Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:9EP:

  • E10: €-1.97
  • GF Value™: €7.57 vs. price of €11.50 (51.9% above fair value)
  • GF Score™: 58/100 with 6 warning signs

No single metric tells the full story. See the STU:9EP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enanta Pharmaceuticals Business Description

Other Exchanges ENTA:USA9EP:Germany
Address 4 Kingsbury Avenue, Watertown, MA, USA, 02472
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.
58GF Score

Get the complete analysis for STU:9EP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.50
Price
€7.57
GF Value